Altis Labs, which develops AI-supported computational imaging to accelerate clinical trials, has raised $6 million in seed funding to further develop its technology.
The funds will be used to advance the company’s Nota platform that uses AI imaging biomarker technology for solid tumor types and other therapeutic areas, the company said in a June 21 release. Drugmakers like Bayer already use the platform to analyze imaging data from phase 1-3 clinical trials, Altis said.
Computational imaging is the process of indirectly forming images from measurements using algorithms that rely on a significant amount of computing.
Benchstrength—formerly part of General Catalyst—and Debiopharm Innovation Fund co-led the finance round. Other participants included Doug Foster, the former CEO of Verana Health, and Richard Gliklich, the founder and CEO of data company OM1.
“This partnership will help us execute on our mission to reduce the excessive time and cost it takes to bring novel, effective treatments to patients in need,” Felix Baldauf-Lenschen, Altis’ co-founder and CEO, said in the release.
The Nota platform analyzes clinical trial imaging data to generate model predictions that provide researchers with more accurate snapshots of a patient at baseline and measure the effect of treatments across subpopulations. The idea is to generate higher-quality insights earlier in clinical development that can in turn increase the chances of successful late-stage trials. Altis said the data also helps developers make critical R&D decisions earlier and can inform trial design, reimbursement strategy and revivals of shelved therapies.